What's missing is more telling than what is present
This poor PR, or more precisely the lack of any HIV PR today linked to the Gates Foundation, is the proof, right from the company, that the Gates Foundation grant announced Friday was not aimed at Leronlimab nor at Cytodyn.
Otherwise they would have PR'ed it, compared to this half-baked, unrelated one.
PS : and don't get me started on "survival rates that compare favourably". It's very easy to distort these statistical figures, that's what Cytodyn's statisticians have done every previous time for several years now. And every time the results were finally ... rejected for further development.
Market Data 
Markets 
